3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Ovarian Neoplasms
3
Mesothelioma, Malignant
3
Solid Tumors
2
Neoplasm Metastasis
2
Disease Progression
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Salivary Gland Neoplasms
1
Parathyroid Neoplasms
1
Neoplasms
1
Lymphoma, Large B-Cell, Diffuse
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Esthesioneuroblastoma, Olfactory
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Medullary
1
Carcinoma, Hepatocellular
1
Advanced Solid Tumors
1
Adenocarcinoma, Follicular
1
Interventions
Rituximab
187
Cyclophosphamide
174
Etoposide
94
Peripheral Blood Stem Cell Transplantation
90
Vincristine
89
Prednisone
80
Doxorubicin
79
Filgrastim
75
fludarabine phosphate
60
Radiotherapy
56
Mycophenolic Acid
41
Melphalan
41
Cytarabine
41
Busulfan
40
Cyclosporine
39
Methotrexate
37
Whole-Body Irradiation
36
Tacrolimus
35
Carmustine
34
Ifosfamide
28
Lenalidomide
27
Granulocyte Colony-Stimulating Factor
27
Antilymphocyte Serum
27
Gemcitabine
25
Carboplatin
25
Methylprednisolone
24
ibritumomab tiuxetan
23
Bortezomib
22
Dexamethasone
21
ibrutinib
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoma, Large B-Cell, Diffuse
×
tumor necrosis factor-alpha, CNGRC fusion protein, human
×
Clear all
NCT03536039
2022-08-03
INGRID
IRCCS San Raffaele
Phase 2
Completed
28 enrolled